This randomized parallel clinical trial will be performed among overweight or obese (BMI>25 kg/m2)type 2 diabetic women aged 30-60 y. Individuals with the use of medications affecting inflammatory biomarkers and adipocytokines and also those with the chronic conditions affecting these biomarkers would not be included in the study. At baseline, we would have a 2-week run-in period for all participants. During this period, 3-day diet records as well as 3-day physical activity records would be collected. Then, after matching for age, BMI, current medication use and menopausal status, participants will be randomely assigned to consume low-energy dense diet, high-energy dense diet or usual diabetes meal plan for 8 weeks. Biochemical indicators (Fasting plasma glucose, serum insulin levels, serum lipid profiles, serum levels of hs-CRP, hs-TNF-alpha, hs-IL-6, Adiponectin, Visfatin and Chemerin)as well as anthropometric measures will be assessed at baseline and after 8 weeks. Low-energy dense diet would be a weight loss diet (-500kcal) containing 50-60% of energy from carbohydrates, 25% from fats and 15-20% from proteins. Individuals adhereing to this diet would have higher intakes of fruits, vegetables and beverages and lower intakes of dietary fat. High-energy dense diet would be a weight loss diet (-500kcal) containing 45-50% of energy from carbohydrates, 35% from fats and 15-20% from proteins. Individuals adhereing to this diet would have lower intakes of fruits and vegetables and higher intakes of dietary fat. Usual Diabetes meal plan would be a conventional weight loss diet (-500 kcal) containing 50-55% of energy from carbohydrates, 30% from fat and 15-20% from proteins. To assess compliance, participants will be asked to obtain a 24-hour dietary recall once in a 2 weeks during the study period. Also, they will be asked to obtain three daily physical activity records during this period. All biochemical measures and anthropometric assessments will be done at the end of trial.